




Figure 1

	Dupilumab	Placebo
19:49541484:C:G_G	Annualized exacerbation	Annualized exacerbation
0 (C/C)	0.35 (464)	0.86 (201)
1 (C/G)	0.87 (140)	0.96 (55)
2 (G/G)	1.61 (9)	2.82 (7)
Variant-treatment interaction p-value	8.7E-03	

Figure 2

Cohort	Trait	Num_Cases	AAF
DRI12544_EFC13579_EUR_Dupilumab_Placebo	EXAC_CT_X_TRT	926	0.13
DRI_EFC_Dupilumab_EUR	EXAC_CT	649	0.129
EFC13579_EUR_Dupilumab	EXAC_CT	422	0.139
DRI12544_EUR_Dupilumab	EXAC_CT	225	0.109
DRI12544_EFC13579_EUR_Placebo	EXAC_CT	277	0.131
EFC13579_EUR_Placebo	EXAC_CT	226	0.14
DRI12544_EUR_Placebo	EXAC_CT	51	0.092

Figure 3




Figure 3 (cont.)

Trait	Arm	Effect	Pval	AAF	Num Cases	Cases Hel	Cases	Hum	Num	Contr	Controls	H	Controls	H
Loss-of-asthma-control%	Dupilumab	1.684	3.62E-03	0.139	272	85	6	6	382	79	3			
	Dupilumab	2.039	1.33E-04	0.139	156	56	5	5	498	108	4			
FEV1 week12	Dupilumab	-0.108	1.85E-01	0.140	648	163	9	9						
FEV1PP week12	Dupilumab	-0.118	1.47E-01	0.140	648	163	9	9						
AQLQ week12	Dupilumab	-0.165	5.47E-02	0.140	576	143	9	9						
Loss-of-asthma-control%	Placebo	0.815	4.29E-01	0.136	161	33	4	4	115	28	3			
	Placebo	1.004	9.89E-01	0.136	100	20	4	4	176	41	3			
FEV1 week12	Placebo	0.022	8.42E-01	0.133	275	61	6	6						
FEV1PP week12	Placebo	0.026	8.12E-01	0.133	275	61	6	6						
AQLQ week12	Placebo	-0.041	7.57E-01	0.128	247	53	5	5						
Red blood cell baseline	baseline	0.039	4.83E-01	0.138	930	225	16	16						
Peak expiratory flow pm	baseline	-14.102	3.78E-02	0.138	929	225	16	16						
Peak expiratory flow am	baseline	-13.618	4.69E-02	0.138	929	225	16	16						

Figure 4